Damora Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	14.8	9.69	10.5	12.69	13	13.74
Research & Development	49.98	201.19	10.79	23.77	48.21	38.49
Other Operating Expenses	-	-	0.97	3.45	-	-
Total Operating Expenses	64.77	210.87	22.26	39.91	61.21	52.23
Operating Income	-239.08	-210.87	-22.26	-39.91	-61.21	-52.23
Interest Income	-	1.17	0.84	-	-	-
Other Non-Operating Income (Expense)	4.09	1	0.88	1.56	-0.42	0.48
Total Non-Operating Income (Expense)	4.09	2.17	1.72	1.56	-0.42	0.48
Pretax Income	-235	-209.79	-21.4	-38.35	-61.62	-51.75
Provision for Income Taxes	-0.09	-0.05	-0.04	-	-	-
Net Income	-235.09	-209.84	-21.44	-38.35	-61.62	-51.75
Net Income to Common	-235.09	-209.84	-21.44	-38.35	-61.62	-51.75
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	10	1	1	1	1	1
Shares Outstanding (Diluted)	10	1	1	1	1	1
Shares Change	689.80%	17.79%	8.87%	4.58%	0.58%	452.45%
EPS (Basic)	5.28	3.98	-18.53	-36.08	-60.75	-51.25
EPS (Diluted)	5.28	3.98	-18.53	-36.08	-60.75	-51.25
EPS Growth	-	-	-	-	-	-
Free Cash Flow	-24.89	-6.73	-18.62	-36.91	-43.13	-52.53
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Per Share	-2.59	-4.93	-16.09	-34.73	-42.43	-51.99
EBITDA	-238.99	-210.84	-22.08	-39.08	-60.72	-51.79
EBIT	-239.08	-210.87	-22.26	-39.91	-61.21	-52.23
Effective Tax Rate	0.04%	0.02%	0.19%	0.00%	0.00%	0.00%

SEC Filings: 10-K · 10-Q